Related Experiment Video

Updated: Jul 18, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.3K

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review

Raj Roy1, Saketh Vinjamuri1, Rishabh Baskara Salian2

  • 1Internal Medicine, Gandhi Medical College and Hospital, Secunderabad, IND.

Cureus
|August 21, 2023
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors significantly reduce heart failure hospitalizations and cardiovascular death. These SGLT-2 inhibitors are safe and effective for managing heart failure patients, improving their quality of life.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Heart failure is a major cause of mortality and hospitalization.
  • Despite advancements, heart failure management remains challenging.
  • Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel therapeutic class.

Purpose of the Study:

  • To conduct an umbrella review of meta-analyses on SGLT-2 inhibitors for heart failure.
  • To synthesize evidence on the efficacy and safety of SGLT-2 inhibitors in heart failure patients.
  • To assess the impact of SGLT-2 inhibitors on hospitalization, mortality, and quality of life.

Main Methods:

  • Umbrella review of meta-analyses.
  • Searched five databases: PubMed, Cochrane Library, Scopus, Global Index Medicus, Science Direct.
  • Included meta-analyses of 5+ RCTs; assessed quality using AMSTAR.

Main Results:

  • 10 meta-analyses including 171,556 patients were analyzed.
  • SGLT-2 inhibitors significantly reduced heart failure hospitalizations.
  • SGLT-2 inhibitors decreased cardiovascular death, all-cause mortality, and serious adverse events.
  • Improved quality of life was observed in patients treated with SGLT-2 inhibitors.

Conclusions:

  • SGLT-2 inhibitors demonstrate significant benefits in reducing adverse cardiovascular outcomes in heart failure.
  • The findings support the safety and efficacy of SGLT-2 inhibitors for heart failure management.
  • SGLT-2 inhibitors represent a valuable therapeutic option for improving patient outcomes in heart failure.

Keywords:
cardiology researchheart failure hospitalizationheart failure prognosissglt2 inhibitors and heart failuresodium-glucose cotransporter-2 (sglt-2) inhibitors

More Related Videos

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K
Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

2.4K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364